The Global 5-Aminosalicylic Acid (CAS 89-57-6) Market was valued at USD 1.87 Billion in 2025 and is projected to reach USD 3.21 Billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 6.2% during the forecast period (2026–2034). This growth is being driven by the rising global prevalence of inflammatory bowel disease (IBD), increasing awareness regarding early diagnosis, and expanding access to gastrointestinal care across emerging economies.

As the pharmaceutical industry intensifies its focus on chronic gastrointestinal conditions, the spotlight falls on the key manufacturers and API producers who are advancing formulation innovation, supply chain resilience, and patient-centric therapy solutions. In this blog, we profile the Top 10 Companies in the 5-Aminosalicylic Acid (CAS 89-57-6) Industry—a mix of established API manufacturers, branded drug developers, and generic pharmaceutical leaders shaping the future of global IBD treatment.

---

🙘 1. Huateng Pharmaceutical Co., Ltd.

Headquarters: China
Key Offering: Pharmaceutical-grade 5-Aminosalicylic Acid (5-ASA) API

Huateng Pharmaceutical is among the leading producers of 5-ASA active pharmaceutical ingredients globally, supplying high-purity mesalamine to pharmaceutical manufacturers across multiple continents. The company operates GMP-certified production facilities and maintains a consistent supply of pharmaceutical-grade 5-ASA that meets USP and EP pharmacopeial standards, making it a preferred sourcing partner for finished dosage formulators treating ulcerative colitis and related IBD conditions.

Key Strengths:

• GMP-certified manufacturing facilities with stringent quality controls

• Reliable large-scale API supply for global pharmaceutical clients

• Compliance with international pharmacopeial standards (USP/EP)

Download FREE Sample Report:
5-Aminosalicylic acid (CAS 89-57-6) Market – View in Detailed Research Report

---

9️⃣ 2. Capot Chemical Co., Ltd.

Headquarters: China
Key Offering: 5-Aminosalicylic Acid API and Custom Synthesis

Capot Chemical is a well-established Chinese chemical manufacturer recognized for its production of high-purity 5-ASA and related pharmaceutical intermediates. The company serves both research institutions and commercial pharmaceutical manufacturers, offering custom synthesis capabilities alongside standard API supply. Capot's strong regulatory compliance record and established presence across global distribution networks have positioned it as a competitive supplier in the rapidly expanding mesalamine market.

Key Strengths:

• Broad product portfolio including pharmaceutical intermediates and fine chemicals

• Custom synthesis capabilities supporting diverse client formulation needs

• Strong export footprint across North America, Europe, and Asia-Pacific

---

8️⃣ 3. Otsuka Chemical Co., Ltd.

Headquarters: Japan
Key Offering: Premium-grade 5-Aminosalicylic Acid API

Otsuka Chemical occupies a distinct premium segment in the global 5-ASA market, leveraging Japan's reputation for precision manufacturing and rigorous quality standards. The company's specialized production technologies deliver exceptionally high-purity 5-ASA with tightly controlled impurity profiles, making its API particularly valued by innovator pharmaceutical companies developing branded mesalamine formulations. Otsuka Chemical's technical expertise and advanced synthesis capabilities differentiate it meaningfully from volume-focused Asian competitors.

Key Strengths:

• Premium synthesis technologies yielding superior purity profiles

• Preferred supplier for innovator and specialty pharmaceutical manufacturers

• Established track record in regulatory compliance across major global markets

---

7️⃣ 4. Dr. Reddy's Laboratories Ltd.

Headquarters: Hyderabad, India
Key Offering: Mesalamine API and Finished Dosage Formulations

Dr. Reddy's Laboratories is one of India's most prominent pharmaceutical companies, with a significant presence in both API manufacturing and finished dosage forms for IBD treatment. The company holds USFDA-approved manufacturing facilities and markets mesalamine-based products across the United States, Europe, and emerging markets. Its integrated API-to-formulation capabilities give it a distinct competitive advantage, enabling cost-effective production and greater control over supply chain quality from synthesis through final packaging.

Key Strengths:

• USFDA-approved manufacturing facilities with global regulatory clearances

• Integrated API and finished dosage manufacturing capabilities

• Strong commercial presence across the United States, Europe, and Asia

Download FREE Sample Report:
5-Aminosalicylic acid (CAS 89-57-6) Market – View in Detailed Research Report

---

6️⃣ 5. Lupin Ltd.

Headquarters: Mumbai, India
Key Offering: Mesalamine Generic Formulations and API

Lupin Ltd. is a globally recognized Indian pharmaceutical manufacturer with a robust portfolio of generic gastrointestinal therapeutics, including mesalamine delayed-release formulations marketed across the United States and other regulated markets. The company's strong generics pipeline and established FDA-regulated manufacturing infrastructure have made it a competitive force in the mesalamine segment, where it competes on the basis of formulation quality, pricing efficiency, and reliable supply. Lupin's expanding API capabilities further strengthen its vertical integration in the 5-ASA value chain.

Key Strengths:

• Comprehensive generic formulations portfolio with regulatory approvals in key markets

• Strong USFDA-regulated manufacturing and quality assurance infrastructure

• Competitive pricing strategy driven by efficient large-scale production

---

5️⃣ 6. Ningbo Inno Pharmchem Co., Ltd.

Headquarters: Ningbo, China
Key Offering: Research-grade and Pharmaceutical-grade 5-ASA, Custom Synthesis

Ningbo Inno Pharmchem has carved out a recognized niche in the 5-ASA market through its focus on custom synthesis and research-grade pharmaceutical ingredients. The company serves both academic research institutions and commercial drug developers seeking tailored 5-ASA specifications for specialized formulation work. However, its capabilities extend into commercial pharmaceutical supply as well, with an emphasis on delivering high-purity API batches with consistent impurity profiles that meet the demands of rigorous regulatory submissions in developed markets.

Key Strengths:

• Specialized custom synthesis capabilities for research and commercial clients

• Flexible batch sizes accommodating both development-scale and commercial-scale orders

• Strong documentation practices supporting regulatory submission requirements

---

4️⃣ 7. Zhangjiagang Xiehe Chemical Co., Ltd.

Headquarters: Zhangjiagang, China
Key Offering: 5-Aminosalicylic Acid API for Pharmaceutical Manufacturing

Zhangjiagang Xiehe Chemical is an established Chinese producer of 5-ASA, supplying pharmaceutical-grade API to domestic and international drug manufacturers engaged in IBD therapy production. The company's manufacturing operations are aligned with GMP standards, and its product quality has been validated through long-standing commercial relationships with formulation companies across Asia and Europe. Its competitive cost structure and reliable production capacity make it a stable supplier in a market characterized by strong volume demand for generic mesalamine products.

Key Strengths:

• GMP-aligned manufacturing with competitive cost efficiencies

• Established supply relationships with Asian and European formulators

• Consistent batch quality supporting long-term commercial API procurement contracts

---

3️⃣ 8. Aurobindo Pharma Ltd.

Headquarters: Hyderabad, India
Key Offering: Mesalamine API and Generic Finished Dose Products

Aurobindo Pharma is one of India's largest pharmaceutical exporters, with an extensive generics portfolio that includes mesalamine formulations for the treatment of ulcerative colitis. The company's multiple USFDA-approved manufacturing facilities and strong presence in the United States generic drug market make it a significant commercial player in the 5-ASA finished dosage space. Aurobindo's broad therapeutic coverage and well-developed regulatory affairs capabilities enable it to efficiently navigate approvals across multiple geographies, accelerating its market access for mesalamine products.

Key Strengths:

• Multiple USFDA-approved facilities supporting large-scale generic drug production

• Extensive US generics market presence with established distribution channels

• Efficient regulatory affairs capabilities enabling multi-market product approvals

Get Full Report Here:
5-Aminosalicylic acid (CAS 89-57-6) Market – View in Detailed Research Report

---

2️⃣ 9. Shandong New Time Pharmaceutical Co., Ltd.

Headquarters: Shandong, China
Key Offering: 5-Aminosalicylic Acid API and Pharmaceutical Intermediates

Shandong New Time Pharmaceutical is a China-based manufacturer that has built a solid commercial position in the 5-ASA API market through investments in production scale and quality management systems. The company supplies mesalamine API to both domestic Chinese pharmaceutical manufacturers and export markets, benefiting from China's established position as the world's dominant source of 5-ASA production. Its continued investment in manufacturing infrastructure and quality compliance positions it well to meet growing demand driven by expanding IBD patient populations across Asia and beyond.

Key Strengths:

• Large-scale production capacity aligned with growing global API demand

• Dual focus on domestic supply and export market development

• Ongoing investment in quality management and manufacturing upgrades

---

1️⃣ 10. Zydus Lifesciences Ltd.

Headquarters: Ahmedabad, India
Key Offering: Mesalamine Finished Dose Formulations and API

Zydus Lifesciences is a leading Indian pharmaceutical company with a diversified portfolio of gastrointestinal therapies, including mesalamine-based products marketed across the United States and other regulated international markets. The company's strong research and development pipeline, combined with robust USFDA-approved manufacturing capabilities, allows it to compete effectively in the generic mesalamine segment while also exploring innovative delivery mechanisms designed to improve patient adherence and clinical outcomes. Zydus' commitment to quality and its expanding global commercial footprint make it one of the most dynamic players in the current 5-ASA landscape.

Key Strengths:

• Active R&D pipeline focused on improved mesalamine delivery systems

• USFDA-approved manufacturing with a strong US generics market presence

• Expanding international commercial operations across regulated and emerging markets

Get Full Report Here:
5-Aminosalicylic acid (CAS 89-57-6) Market – View in Detailed Research Report

---

🌎 Outlook: The Future of the 5-ASA Market Is Innovation-Driven and Globally Expanding

The 5-Aminosalicylic acid market is undergoing a meaningful evolution. While generic mesalamine continues to dominate volume consumption as the cornerstone first-line therapy for mild-to-moderate ulcerative colitis, the industry is simultaneously investing in next-generation delivery technologies, expanded geographic reach, and integrated patient support models that go well beyond the compound itself.

📈 Key Trends Shaping the Market:

• Rapid growth in IBD patient populations across Asia-Pacific, Latin America, and the Middle East driving new demand for 5-ASA formulations

• Shift toward once-daily extended-release oral mesalamine formulations improving patient adherence and long-term disease remission rates

• Consolidation of API production in India and China creating supply chain efficiencies while prompting risk mitigation strategies among global formulators

• Growing interest in digital health tools and remote patient monitoring as complementary assets alongside 5-ASA maintenance therapy

• Increasing regulatory scrutiny of mesalamine formulation changes driving investment in robust bioequivalence and clinical data packages

The companies profiled above are not only supplying a critical therapeutic agent to millions of IBD patients worldwide—they are actively shaping the future of gastrointestinal pharmacotherapy through formulation innovation, manufacturing excellence, and strategic global expansion. As the market grows from USD 1.87 Billion in 2025 toward a projected USD 3.21 Billion by 2034, these industry leaders will be central to ensuring that effective, accessible mesalamine therapy reaches every patient who needs it, wherever they are in the world.